Association of hematological parameters on polymorphisms of HFE gene (rs1800562, rs1800730, rs1799945) in non-alcoholic fatty liver disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Non-alcoholic fatty liver disease and its associated metabolic syndrome are one of the most common chronic liver diseases among adults worldwide. One of the reasons associated with unfavorable course may be an abnormalities of iron metabolism associated with of fatty liver degeneration, caused by the presence of a certain polymorphic locus of the HFE gene.

Aim. Study the dependence of changes in hematological parameters on HFE gene polymorphisms among patients with non-alcoholic fatty liver disease with metabolic syndrome and normal body weight.

Materials and methods. The study included 173 patients, of which 85 people had NAFLD and normal body weight, 88 people had NAFLD and metabolic syndrome. All patients underwent genotyping of the rs1800562, rs1800730, rs1799945 polymorphisms of the HFE gene, as well as assessment of hematological parameters. Statistical analysis was performed out using the Statistica 10 package.

Results. Patients with NAFLD and normal body weight were characterized by the presence of the AT genotype of the rs1800730 polymorphism and the CG and GG genotypes of the rs1799945 polymorphism. In patients with NAFLD and metabolic syndrome, genotypes AA and TT of the rs1800730 polymorphism and CC of the rs1799945 polymorphism were more common.

Changes in hematological parameters were noted in both groups. In patients with normal body weight, an increase in ESR and monocytosis was observed. Patients with metabolic syndrome had anemia, increased ESR and pancytopenia.

Conclusion. Patients with NAFLD and normal body weight are characterized by the AT genotypes of the rs1800730 polymorphism and the CG and GG genotypes of the rs1799945 polymorphism. In patients with metabolic syndrome, variants of the AA polymorphism rs1800730 and CC polymorphism rs1799945 are more common. The rs1800562 polymorphism did not show significant differences in prevalence when compared between groups.

In patients with normal body weight, changes in hematological parameters are less pronounced, an increase in ESR and monocytosis is noted. In patients with metabolic syndrome, on the contrary, disturbances in hematological parameters are more pronounced; panleukopenia, increased ESR, and anemia are noted.

The changes we discovered may be evidence that in patients with NAFLD and normal body weight, steatosis and chronic inflammation predominated, and in patients with metabolic syndrome and NAFLD, steatohepatitis, which has a negative effect on organ systems. One of the risk factors for its development was the AA genotype of the rs800730 polymorphism and the CC genotype of the rs1799945 polymorphism.

Full Text

Restricted Access

About the authors

O. V. Smirnova

Research Institute for Medical Problems in the North - Division of Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the RAS»; Siberian Federal University

Author for correspondence.
Email: ovsmirnova71@mail.ru
ORCID iD: 0000-0003-3992-9207

доктор медицинских наук, профессор, заведующая лабораторией клинической патофизиологии, профессор кафедры медицинской биохимии

Russian Federation, Krasnoyarsk; Krasnoyarsk

D. V. Lagutinskaya

Research Institute for Medical Problems in the North - Division of Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the RAS»; Siberian Federal University

Email: dlagut1210@gmail.com
ORCID iD: 0000-0003-1295-9262

аспирант, младший научный сотрудник, ассистент кафедры медицинской биохимии

Russian Federation, Krasnoyarsk; Krasnoyarsk

References

  1. Madaleine, G. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation / G. Madaleine, A. Majumdar // World Journal of Hepatology. – 2020. – V. 12, № 12. – P. 1168-1181. https://doi.org/10.4254/wjh.v12.i12.1168.
  2. Vernon, G. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults / G. Vernon, A. Baranova, Z.M. Younossi // Alimentary Pharmacology & Therapeutics. – 2011. – V. 34, № 3. – P. 274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x.
  3. Yki-Jarvinen, H. Dietary carbohydrates and fats in nonalcoholic fatty liver disease / H. Yki-Jarvinen, P. Luukkonen, L. Hodson [et al.] // Nature Reviews Gastroenterology & Hepatology. – 2021. – V. 18, № 11. – P. 770-786. https://doi.org/10.1038/s41575-021-00472-y.
  4. Speliotes, E. Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits / E. Speliotes, L. Yerges-Armstrong, J. Wu [et al.] // PloS Genetics. – 2011. – V. 7, № 3. – P. e1001324. https://doi.org/10.1371/journal.pgen.1001324.
  5. Basyte-Bacevice, V. TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis / V. Basyte-Bacevice, J. Skieceviciene, I. Valantiene [et al.] // International Journal of Molecular Sciences. – 2019. – V. 20. – P. 1277. https://doi.org/10.3390/ijms20061277.
  6. Corridani, E. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD / E. Corradini, E. Buzzetti, P. Dongiovanni [et al.] // Journal of Hepatology. – 2021. – V. 75. – P. 506-513. https://doi.org/10.1016/j.jhep.2021.03.014.
  7. Lebron, J. Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor / J. Lebron, M. Bennett, D. Vaughn [et al.] // Cell. – 1998. – V. 93, № 1. – P. 111-123. https://doi.org/10.1016/s0092-8674(00)81151-4.
  8. Billesbolle, C. Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms / C. Billesbolle, C. Azumaya, R. Kretsch [et al.] // Nature. – 2020. – V. 586, № 7831. – P. 807-811. https://doi.org/10.1038/s41586-020-2668-z.
  9. Nelson, J. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations / J. Nelson, E. Brunt, K. Kowdley // Hepatology. – 2012. – V. 56, № 5. – P. 1730-1740. https://doi.org/10.1002/hep.25856.
  10. Ye, Q. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls / Q. Ye, B. Qian, W. Yin [et al.] // PloS One. – 2016. – V. 11, № 9. – P. e0163423. https://doi.org/10.1371/journal.pone.0163423.
  11. Смирнова О. В., Савченко А.А., Манчук В.Т. Особенности клеточного и гуморального иммунитета у больных острыми нелимфобластным и лимфобластным лейкозами // Сибирский медицинский журнал (Иркутск). – 2006. – Т. 59. – № 1. – С. 35-38.
  12. Смирнова О. В., Савченко А.А., Манчук В.Т. Метаболический статус лимфоцитов крови при хроническом миелолейкозе и хроническом лимфолейкозе // Медицинская иммунология (Санкт-Петербург). – 2008. – Т. 10. – № 1. – С. 21-26.
  13. Москаленко О.Л., Смирнова О.В., Каспаров Э.В., Зайцева О.И. Диагностика метаболического синдрома на современном этапе // Siberian Journal Of Life Sciences And Agriculture (Красноярск). – 2019. – Т. 11. – № 5. – С. 94-100.
  14. Смирнова О. В., Титова Н. М., Елманова Н. Г. Роль прооксидантной системы в прогрессировании миеломной болезни // Врач-аспирант (Воронеж). – 2013. – Т. 60. – № 5.1. – С. 152-157.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Smirnova O.V., Lagutinskaya D.V.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies